Avelumab

Phase 1/2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Neuroendocrine Carcinoma

Conditions

Neuroendocrine Carcinoma

Trial Timeline

Nov 15, 2017 → Mar 12, 2020

NCT ID

NCT03278405

About Avelumab

Avelumab is a phase 1/2 stage product being developed by Merck for Neuroendocrine Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03278405. Target conditions include Neuroendocrine Carcinoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03089658	Pre-clinical	Completed	—	—	Metastatic Merkel Cell Carcinoma
NCT06412848	Pre-clinical	Active	May 9, 2024	Jun 30, 2026	Urothelial Carcinoma
NCT05600127	Phase 2	Recruiting	Dec 1, 2022	Dec 1, 2026	Urothelial Carcinoma
NCT05431777	Pre-clinical	Completed	Jul 19, 2022	Jan 16, 2023	Urothelial Carcinoma
NCT05366725	Pre-clinical	Completed	Jun 29, 2022	Jun 27, 2024	Urothelial Cancer
NCT04822350	Pre-clinical	Completed	Jul 13, 2021	Apr 25, 2024	Urothelial Carcinoma
NCT03815643	Phase 3	Active	Mar 22, 2019	Feb 19, 2027	Solid Tumors
NCT03514719	Phase 1	Completed	Oct 1, 2018	Dec 2, 2021	Non Small Cell Lung Cancer
NCT03568097	Phase 2	UNKNOWN	Sep 16, 2018	Apr 1, 2024	Small Cell Lung Carcinoma
NCT03827044	Phase 3	Terminated	Aug 31, 2018	Jan 5, 2022	POLE Exonuclease Mutant Colon Cancer
NCT03674424	Phase 2	Completed	Jun 1, 2018	Jan 30, 2025	Non-metastatic Muscle Invasive Bladder Cancer
NCT03439501	Phase 2	UNKNOWN	Jan 16, 2018	Mar 30, 2022	Lymphoma, Extranodal NK-T-Cell
NCT03147404	Phase 2	Completed	Dec 28, 2017	Jul 22, 2019	Neuroendocrine Carcinoma, Grade 3
NCT03352934	Phase 2	Completed	Dec 7, 2017	Feb 18, 2022	Cancer
NCT03389126	Phase 2	Completed	Dec 1, 2017	Jan 31, 2020	Carcinoma, Hepatocellular
NCT03278379	Phase 2	Completed	Nov 15, 2017	Jul 6, 2023	Neuroendocrine Tumors
NCT03278405	Phase 1/2	Completed	Nov 15, 2017	Mar 12, 2020	Neuroendocrine Carcinoma
NCT03403777	Phase 2	Completed	Nov 15, 2017	Feb 28, 2019	Testicular Neoplasms
NCT03491345	Phase 2	UNKNOWN	Aug 1, 2017	Dec 1, 2022	PD-L1 Positive Mutation Tumor
NCT03244176	Phase 1	Active	Jul 21, 2017	Jul 1, 2025	Lymphomas Non-Hodgkin's B-Cell

Competing Products

20 competing products in Neuroendocrine Carcinoma

See all competitors

Product	Company	Stage	Hype Score
[203Pb]VMT-α-NET + [212Pb]VMT-α-NET	Perspective Therapeutics	Phase 1/2	33
[203Pb]VMT-α-NET	Perspective Therapeutics	Phase 1	25
[212Pb] VMT-α-NET	Perspective Therapeutics	Phase 1	25
Lenvatinib	Eisai	Phase 2	52
Abemaciclib	Eli Lilly	Phase 2	52
Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide.	Jiangsu Hengrui Medicine	Phase 3	77
Famitinib	Jiangsu Hengrui Medicine	Phase 2	52
68Ga-DOTATOC	Jiangsu Hengrui Medicine	Phase 3	77
Olaparib	AstraZeneca	Phase 2	52
Pembrolizumab	Merck	Phase 2	52
Lenvatinib + Pembrolizumab + Hyperpolarized 13C-Pyruvate	Merck	Phase 2	52
Pembrolizumab	Merck	Phase 2	52
Pembrolizumab Injection	Merck	Phase 2	52
Carboplatin + Cisplatin + Docetaxel + Etoposide + Pembrolizumab	Merck	Phase 1	33
Avelumab	Merck	Phase 2	52
Pembrolizumab + Lenvatinib	Merck	Phase 2	52
Avelumab	Merck	Phase 2	52
Pembrolizumab + Irinotecan + Paclitaxel	Merck	Phase 2	52
MK-0646	Merck	Phase 2	52
Lanreotide + Pembrolizumab	Merck	Phase 1/2	41

Other Products from Merck

DuleraApproved

ImipenemApproved

Mavenclad®Approved

raltegravir + PlaceboApproved

alendronate sodiumApproved